User contributions for Alara E. Dagsali

24 April 2024

• 21:2321:23, 24 April 2024 diff hist +3 Tranexamic No edit summary Tag: Visual edit: Switched
• 21:2221:22, 24 April 2024 diff hist −1 Tranexamic No edit summary
• 21:2121:21, 24 April 2024 diff hist +88 N Template:AlaraE.Dagsali Created page with " Alara Ece Dagsali, M.D.[mailto:alaraecedagsali99@gmail.com]"
• 21:1421:14, 24 April 2024 diff hist +23,020 N Tranexamic Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Tranexamic |aOrAn=a |drugClass=hemophilia drug |indicationType=prevention |indication=Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. |adverseReactions=Thromboembolic Risk Seizures Hypersensitivity Reactions Visual Disturbances Dizzines..."

22 April 2024

• 18:4418:44, 22 April 2024 diff hist 0 N File:D2f97c72-bbfb-426e-b742-6e25234ba1ff 2.jpg No edit summary current
• 18:4318:43, 22 April 2024 diff hist 0 N File:Ae8d4ea7-c895-403b-a435-56dc4996a3b0.JPG No edit summary current

21 March 2024

• 16:5516:55, 21 March 2024 diff hist +43 Norelgestromin No edit summary
• 16:5316:53, 21 March 2024 diff hist +12,388 Norelgestromin No edit summary
• 16:2816:28, 21 March 2024 diff hist +22,456 Norelgestromin No edit summary
• 08:4608:46, 21 March 2024 diff hist +1,580 Norelgestromin No edit summary
• 08:3508:35, 21 March 2024 diff hist +929 Norelgestromin No edit summary
• 08:3308:33, 21 March 2024 diff hist +3,183 N Norelgestromin Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=NORELGESTROMIN AND ETHINLY ESTRADIOL patch |indicationType=prevention |indication=Norelgestromin and ethinyl estradiol transdermal system is indicated for the prevention of pregnancy in women with a body mass index (BMI) < 30 kg/m for whom a combined hormonal contraceptive is appropriate. |hasBlackBoxWarning=Yes |adverseReactions=The following serious adverse reactions with the use of co..."

15 February 2024

• 02:0902:09, 15 February 2024 diff hist +1,330 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC) No edit summary
• 02:0102:01, 15 February 2024 diff hist 0 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC) No edit summary
• 02:0002:00, 15 February 2024 diff hist −40,428 Coronary heart disease in Diabetics Replaced content with "__NOTOC__ {{ADA guidelines}} {{CMG}} {{AE}} {{SCh}}; {{MehdiP}}; {{TarekNafee}} ==2016 ADA Standards of Medical Care in Diabetes Guidelines<ref name="urlcare.diabetesjournals.org">{{cite web |url=http://care.diabetesjournals.org/content/suppl/2015/12/21/39.Supplement_1.DC2/2016-Standards-of-Care.pdf |title=care.diabetesjournals.org |format= |work= |accessdate=}}</ref>== ===Screening=== {|class="wikitable" | bgcolor="Seashell"|<nowiki>"</nowiki>'''1.'''In asymptomatic..." current Tag: Replaced
• 02:0002:00, 15 February 2024 diff hist +40,625 N 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC) Created page with "{{ADA guidelines}} {{CMG}} {{AE}} {{SCh}}; {{MehdiP}}; {{TarekNafee}} ==2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)<ref name="pmid37622663">{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines f..."
• 01:5501:55, 15 February 2024 diff hist +1,959 Coronary heart disease in Diabetics No edit summary
• 01:5301:53, 15 February 2024 diff hist +958 Coronary heart disease in Diabetics No edit summary
• 01:4801:48, 15 February 2024 diff hist +5,725 Coronary heart disease in Diabetics No edit summary
• 01:3801:38, 15 February 2024 diff hist +2 Coronary heart disease in Diabetics No edit summary
• 01:3301:33, 15 February 2024 diff hist 0 Coronary heart disease in Diabetics No edit summary
• 01:3201:32, 15 February 2024 diff hist −4 Coronary heart disease in Diabetics No edit summary
• 01:1601:16, 15 February 2024 diff hist +1 Coronary heart disease in Diabetics No edit summary
• 01:1401:14, 15 February 2024 diff hist +3,056 Coronary heart disease in Diabetics No edit summary
• 01:0701:07, 15 February 2024 diff hist −45 Coronary heart disease in Diabetics No edit summary
• 01:0401:04, 15 February 2024 diff hist +2,663 Coronary heart disease in Diabetics No edit summary
• 00:1700:17, 15 February 2024 diff hist +6,524 Coronary heart disease in Diabetics No edit summary
• 00:0500:05, 15 February 2024 diff hist 0 Coronary heart disease in Diabetics →Recommendations for nutrition in patients with type 2 diabetes with or without cardiovascular disease (DO NOT EDIT)== Tag: Visual edit
• 00:0400:04, 15 February 2024 diff hist +1,869 Coronary heart disease in Diabetics No edit summary Tag: Visual edit: Switched

31 January 2024

• 20:3020:30, 31 January 2024 diff hist +28,883 N Adagrasib Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E. Dagsali |genericName=adagrasib |aOrAn=an |indicationType=treatment |indication=KRAZATI is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test [see DOSAGE AND ADMINISTRATION (2.1)], who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on ob..."

21 December 2023

• 08:4608:46, 21 December 2023 diff hist +4,642 Coronary heart disease in Diabetics No edit summary
• 07:3407:34, 21 December 2023 diff hist +2,774 Coronary heart disease in Diabetics No edit summary
• 07:2007:20, 21 December 2023 diff hist +1 Coronary heart disease in Diabetics /* Recommendations for assessing cardiovascular risk in patients with type 2 diabetes(DO NOT EDIT){{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/el...
• 07:2007:20, 21 December 2023 diff hist +1 Coronary heart disease in Diabetics /* Recommendations for diagnosing diabetes(DO NOT EDIT){{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/c...
• 07:1907:19, 21 December 2023 diff hist +40 Coronary heart disease in Diabetics /* 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.f...
• 07:1807:18, 21 December 2023 diff hist +503 Coronary heart disease in Diabetics /* Recommendations for assessing cardiovascular risk in patients with type 2 diabetes{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfr...
• 07:1607:16, 21 December 2023 diff hist +1,572 Coronary heart disease in Diabetics /* Recommendations for assessing cardiovascular risk in patients with type 2 diabetes{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfr...
• 07:1207:12, 21 December 2023 diff hist +2,107 Coronary heart disease in Diabetics /* 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.f...
• 07:0207:02, 21 December 2023 diff hist +200 Coronary heart disease in Diabetics No edit summary
• 06:5106:51, 21 December 2023 diff hist +609 Coronary heart disease in Diabetics /* 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.f...
• 06:4906:49, 21 December 2023 diff hist +1,670 Coronary heart disease in Diabetics /* 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes{{cite journal| author=Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ | display-authors=etal| title=2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. | journal=Eur Heart J | year= 2023 | volume= 44 | issue= 39 | pages= 4043-4140 | pmid=37622663 | doi=10.1093/eurheartj/ehad192 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.f...
• 06:3406:34, 21 December 2023 diff hist +2,943 Coronary heart disease in Diabetics No edit summary
• 06:2306:23, 21 December 2023 diff hist +615 Coronary heart disease in Diabetics No edit summary

23 November 2023

• 15:0015:00, 23 November 2023 diff hist +252 Reni Syndrome No edit summary
• 14:4914:49, 23 November 2023 diff hist +30 Reni Syndrome No edit summary
• 14:4814:48, 23 November 2023 diff hist +541 Reni Syndrome →Treatment
• 14:4714:47, 23 November 2023 diff hist −50 Reni Syndrome →Natural History, Complications and Prognosis
• 14:4614:46, 23 November 2023 diff hist +2,996 Reni Syndrome No edit summary
• 14:0914:09, 23 November 2023 diff hist +376 Reni Syndrome →Differential Diagnosis
• 14:0414:04, 23 November 2023 diff hist +12 Reni Syndrome →Pathophysiology